Literature DB >> 16790442

Characterization of mechanisms involved in secretion of active heparanase.

Itay Shafat1, Israel Vlodavsky, Neta Ilan.   

Abstract

Heparanase is an endo-beta-D-glucuronidase involved in extracellular matrix remodeling and degradation and implicated in tumor metastasis, angiogenesis, inflammation, and autoimmunity. The enzyme is synthesized as a latent 65-kDa protein and is processed in the lysosomal compartment to an active 58-kDa heterodimer, where it is stored in a stable form. In contrast, its heparan sulfate substrate is localized extracellularly, suggesting the existence of mechanisms that trigger heparanase secretion. Here we show that secretion of the active enzyme is mediated by the protein kinase A and C pathways. Moreover, secretion of active heparanase was observed upon cell stimulation with physiological concentrations of adenosine, ADP, and ATP, as well as by the noncleavable ATP analogue adenosine 5'-O-(thiotriphosphate). Indeed, heparanase secretion was noted upon cell stimulation with a specific P2Y1 receptor agonist and was inhibited by P2Y receptor antagonists. The kinetics of heparanase secretion resembled the secretion of cathepsin D, a lysosomal enzyme, indicating that the secreted heparanase is of lysosomal origin. We suggest that secretion of active heparanase is initiated by extracellular cues activating the protein kinase A and C signaling pathways. The secreted enzyme(s) then facilitate cell invasion associated with cancer metastasis, angiogenesis, and inflammation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16790442     DOI: 10.1074/jbc.M602762200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  26 in total

1.  Dry eye and designer ophthalmics.

Authors:  Gordon W Laurie; Leslie A Olsakovsky; Brian P Conway; Robert L McKown; Kazuko Kitagawa; Jason J Nichols
Journal:  Optom Vis Sci       Date:  2008-08       Impact factor: 1.973

2.  Macrophage activation by heparanase is mediated by TLR-2 and TLR-4 and associates with plaque progression.

Authors:  Miry Blich; Amnon Golan; Gil Arvatz; Anat Sebbag; Itay Shafat; Edmond Sabo; Victoria Cohen-Kaplan; Sirouch Petcherski; Shani Avniel-Polak; Amnon Eitan; Haim Hammerman; Doron Aronson; Elena Axelman; Neta Ilan; Gabriel Nussbaum; Israel Vlodavsky
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-11-15       Impact factor: 8.311

Review 3.  The Lacritin-Syndecan-1-Heparanase Axis in Dry Eye Disease.

Authors:  Karina Dias-Teixeira; Xavier Horton; Robert McKown; Jeffrey Romano; Gordon W Laurie
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

Review 4.  New potential agents in treating diabetic kidney disease: the fourth act.

Authors:  Mark E Williams
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 5.  Purinergic signalling and cancer.

Authors:  Geoffrey Burnstock; Francesco Di Virgilio
Journal:  Purinergic Signal       Date:  2013-12       Impact factor: 3.765

Review 6.  The mechanisms and physiological relevance of glycocalyx degradation in hepatic ischemia/reperfusion injury.

Authors:  Rowan F van Golen; Megan J Reiniers; Nienke Vrisekoop; Coert J Zuurbier; Pim B Olthof; Jacco van Rheenen; Thomas M van Gulik; Barry J Parsons; Michal Heger
Journal:  Antioxid Redox Signal       Date:  2014-02-19       Impact factor: 8.401

7.  Clinical significance of urine heparanase in bladder cancer progression.

Authors:  Itay Shafat; Dov Pode; Tamar Peretz; Neta Ilan; Israel Vlodavsky; Benjamin Nisman
Journal:  Neoplasia       Date:  2008-02       Impact factor: 5.715

8.  Inverse correlation between HPSE gene single nucleotide polymorphisms and heparanase expression: possibility of multiple levels of heparanase regulation.

Authors:  Olga Ostrovsky; Michael Korostishevsky; Itay Shafat; Margarita Mayorov; Neta Ilan; Israel Vlodavsky; Arnon Nagler
Journal:  J Leukoc Biol       Date:  2009-04-30       Impact factor: 4.962

9.  Prolactin promotes the secretion of active cathepsin D at the basal side of rat mammary acini.

Authors:  Roberta Castino; Serge Delpal; Edwige Bouguyon; Marina Demoz; Ciro Isidoro; Michèle Ollivier-Bousquet
Journal:  Endocrinology       Date:  2008-04-17       Impact factor: 4.736

10.  Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias.

Authors:  Constantine S Mitsiades; Cecile Rouleau; Cinara Echart; Krishna Menon; Beverly Teicher; Maria Distaso; Antonio Palumbo; Mario Boccadoro; Kenneth C Anderson; Massimo Iacobelli; Paul G Richardson
Journal:  Clin Cancer Res       Date:  2009-02-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.